Latest Headlines

  1. Taking The Guesswork Out Of Drug Development For Chagas Disease 4/24/2026

    Researchers at Kent have established a computational protocol that could accelerate the development of more effective treatments for life-threatening parasitic infections such as Chagas disease, by enabling scientists to accurately identify reactions that can result in successful drug candidates without the need for trial and error.

  2. Orion Pharma's ODM-212 Granted Orphan Drug Designation In Mesothelioma By The US FDA 4/23/2026

    Orion Corporation (Orion Pharma) today announced that its investigational drug ODM-212 has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of mesothelioma, which is a rare and difficult to treat cancer.

  3. ImmunoForge To Accelerate CNS Drug Development With Innovative BBB Shuttle Platform 'LMT15' 4/22/2026

    ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company specializing in treatments for rare and muscular diseases, is poised to redefine Central Nervous System (CNS) drug delivery with its proprietary LMT15 Platform, a next-generation Blood-Brain Barrier (BBB) shuttle technology.

  4. Celerion Announces Majority Investment From THL Partners 4/22/2026

    Celerion, a global leader in clinical pharmacology and bioanalytical sciences, today announced a majority investment from THL Partners (“THL”), a premier private equity firm investing in middle market growth companies.

  5. Candidate Breast Cancer Drug Overloads Tumors With 'Surge' Of Toxic Lipids 4/22/2026

    An experimental drug targeting triple-negative breast cancer overwhelms cancer cells with toxic fats, according to new tests on human-derived tumors in mice. Triple-negative breast cancer lacks three common drug targets, making it one of the most aggressive forms of the disease.

  6. Pegrizeprument Granted Orphan Drug Designation For Prevention Of Organ Rejection In Heart Transplant Patients 4/22/2026

    Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, announced today that pegrizeprument (also known as VEL-101), a novel investigational maintenance immunosuppressive agent, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the prophylaxis of heart allograft rejection in patients receiving a heart transplant.

  7. IOI Launches New Antifungal Drug Discovery Programme 4/21/2026

    The Ineos Oxford Institute for antimicrobial research (IOI) has established a new antifungal drug discovery programme to address the growing global threat of fungal infections and antifungal resistance.

  8. Insilico Medicine Announces Industry's First Longevity Board To Accelerate AI-Driven Aging Research For Drug Discovery 4/21/2026

    Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry's first Longevity Board (Board).

  9. Belite Bio Initiates Rolling Submission Of New Drug Application To The U.S. Food And Drug Administration For Tinlarebant For The Treatment Of Stargardt Disease 4/21/2026

    Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has initiated a rolling submission of an New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant, an investigational novel oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disorder caused by mutations in the ABCA4 gene.

  10. Leinco Technologies And CellCarta Collaborate To Advance Proteomics Solutions And Applications For Drug Development 4/20/2026

    Leinco Technologies, a leader in antibody and protein development, and CellCarta, a global provider of precision medicine laboratory services, are pleased to announce a strategic collaboration aimed at advancing proteomics solutions that will benefit the development of immuno-oncology and other targeted therapeutic modalities.